Galderma Group AG (XSWX:GALD) Deferred Tax: CHF62 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GALD Galderma Group AG XSWX:GALD
14 GF Score
Price CHF154.95
View Full Analysis

What is Galderma Group AG Deferred Tax?

Galderma Group AG XSWX:GALD +0.81% 14 Deferred Tax is CHF62 Mil as of Jun. 2026. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100.

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Galderma Group AG's change in deferred tax for the six months ended in Jun. 2026 was CHF88 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Jun. 2026 was CHF62 Mil.

Galderma Group AG Deferred Tax Related Terms

Galderma Group AG Deferred Tax Historical Data

* Premium members only.

The historical data trend for Galderma Group AG's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galderma Group AG Deferred Tax Chart

Galderma Group AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Deferred Tax
-1.84 41.74 58.81 70.44 20.72

Galderma Group AG Semi-Annual Data
Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Deferred Tax Get a 7-Day Free Trial 26.81 43.69 47.17 -25.50 87.92
XSWX:GALD
14GF Score
Galderma Group AG XSWX:GALD
Deferred Tax is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galderma Group AG Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF62 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Deferred Tax →
What does a Deferred Tax of CHF62 Mil mean?
Galderma Group AG (XSWX:GALD) has a Deferred Tax of CHF62 Mil as of Jun. 2026. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Galderma Group AG.
Is Galderma Group AG's Deferred Tax too high?
Galderma Group AG's current Deferred Tax is CHF62 Mil. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's Deferred Tax compare to ZTS and UTHR?
Galderma Group AG's Deferred Tax of CHF62 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Deferred Tax for a Drug Manufacturers company?
A good Deferred Tax depends on the Drug Manufacturers industry context. However, Deferred Tax should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Deferred Tax mean?
A high Deferred Tax can signal that a stock is expensive relative to its fundamentals. Change in Defered Tax is amount of deferred tax assets or liabilities due to temporary differences in financial and tax accounting. View historical data for Galderma Group AG. Galderma Group AG's current Deferred Tax is CHF62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current Deferred Tax of CHF62 Mil. The current Deferred Tax is CHF62 Mil. Galderma Group AG's overall GF Score™ is 14/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Deferred Tax calculated?
Deferred Tax is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current Deferred Tax is CHF62 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galderma Group AG Business Description

Address Zahlerweg 10, Zug, CHE, 6300
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score

Get the complete analysis for XSWX:GALD

Deferred Tax is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF154.95
Price